Stock-based compensation (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Schedule of Service Vesting-Based Stock Option Activity

The following is a summary of service vesting-based stock option activity for the year ended December 31, 2025 and 2024, and the status of service vesting-based stock options outstanding as of December 31, 2025 and 2024:

	2025			2024			2023
	Shares	Wtd. Avg. Exercise Price		Shares	Wtd. Avg. Exercise Price		Shares	Wtd. Avg. Exercise Price
Outstanding as of beginning of year	127,000	$	2.19	217,250	$	2.21	456,293	$	2.17
Exercised	(10,000)	1.83		(90,250)	2.23		(239,043)	2.12
Outstanding at end of year	117,000	$	2.22	127,000	$	2.19	217,250	$	2.21
Stock options exercisable at year end	117,000	$	2.22	127,000	$	2.19	217,250	$	2.21

Schedule of Share-Based Payment Arrangement, Option, Exercise Price Range

The following table summarizes information about service vesting-based stock options exercisable and outstanding as of December 31, 2025:

Range of Exercise Prices	Number Outstanding at December 31, 2025	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price
$1.00 - 1.50	2,000	0.85	$	1.49
$1.51 - 2.00	105,000	0.30	1.90
$2.51 - 8.60	10,000	1.92	5.69
	117,000	0.44	$	2.22

Schedule of Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity

The following is a summary of service vesting-based restricted stock activity for the years ended December 31, 2025 and 2024, and the status of unvested service vesting-based restricted stock outstanding as of December 31, 2025 and 2024:

	2025			2024			2023
	Shares	Wtd. Avg. Grant Date Fair Value		Shares	Wtd. Avg. Grant Date Fair Value		Shares	Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of year	1,295,640	$	16.00	2,312,898	$	18.32	1,879,215	$	28.94
Granted	470,824	25.64		484,886	20.65		1,907,101	13.12
Vested	(599,358)	18.58		(1,323,729)	21.57		(1,237,221)	24.97
Forfeited	(61,532)	17.35		(178,415)	17.09		(236,197)	25.88
Non-vested at year end	1,105,574	$	18.62	1,295,640	$	16.00	2,312,898	$	18.32

The following is a summary of market-based restricted stock activity under our 2023 Plan for the years ended December 31, 2025 and 2024 and the status of market-based restricted stock outstanding as of December 31, 2025 and 2024:

	2025			2024			2023
	Shares	Wtd. Avg. Grant Date Fair Value		Shares	Wtd. Avg. Grant Date Fair Value		Shares	Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of year	495,686	$	25.69	509,166	$	26.50	271,044	$	30.64
Granted	451,801	32.91		312,081	26.61		268,738	25.19
Vested	(470,287)	25.19		(325,561)	27.84		(30,616)	51.65
Non-vested at year end	477,200	$	33.02	495,686	$	25.69	509,166	$	26.50

Schedule of Share-Based Payment Award, Restricted Stock, Valuation Assumptions

The PSA has been modified since its grant date as follows:

(in millions)	Fair Value
Fair value of PSA as of grant date	$	1.9
Q4 2024 change in estimated achievement probability	0.8
Q1 2025 modification	1.6
Cumulative stock compensation expense related to PSA as of December 31, 2025	(4.3)
Remaining unrecognized non-cash compensation costs related to PSA	$	—

Schedule of Share-Based Payment Award, Market-Based Awards Valuation Assumption

The following is a summary of key inputs to our market-based restricted stock awards as of December 31, 2025:

							Fair Value Assumptions
	Grant Date	Target Shares	Vesting Range	Market Condition Period	FV of Award (in millions)		Volatility		Risk Free Rate		Dividend Rate		Attainment %		Vested Shares
2022 TSR	2/24/2022	240,428	0% - 200%	1/1/2022 - 12/31/2023	$	6.7	63	%	1.5	%	—	%	125	%	300,529
2023 TSR(1)	1/3/2023	268,738	0% - 200%	1/1/2023 - 12/31/2024	$	6.8	78	%	4.4	%	—	%	175	%	470,287
2024 TSR(2)	3/8/2024	239,464	0% - 200%	1/1/2024 - 12/31/2025	$	6.3	80	%	4.6	%	—	%	N/A		N/A
2025 TSR	3/18/2025	250,252	0% - 200%	1/1/2025 - 12/31/2026	$	9.8	60	%	4.1	%	—	%	N/A		N/A

(1) Of the $6.8 million fair value of the 2023 Total Shareholder Return ("TSR") award being expensed on a straight-line basis over the grant date to the vesting date, $1.6 million of expense was recognized in 2023 to reflect accelerations in the vesting period of certain awards.

(2) Of the $6.3 million fair value of the 2024 TSR award being expensed on a straight-line basis over the grant date to the vesting date, $0.3 million of expense was recognized in 2024 to reflect accelerations in the vesting period of certain awards.

Schedule of Share-Based Payment Arrangement, Expensed and Capitalized, Amount

We recorded total stock compensation expense for the years ended December 31, 2025, 2024, and 2023, as follows:

	2025		2024		2023
Research and development costs	$	2,499	$	1,558	$	2,076
Sales and marketing costs	1,792		1,620		3,158
General and administrative costs	15,875		10,814		13,213
Cost of revenue	1,105		1,291		1,456
Total	$	21,271	$	15,283	$	19,903

(1) During the years ended December 31, 2025 and 2024, $21 thousand and $18 thousand, respectively, of stock compensation expenses were capitalized to internal use software. No stock compensation expenses were capitalized into internal use software during the year ended December 31, 2023.